A Phase 3, Multicenter, Open-label, Uncontrolled, Long-term Trial to Evaluate the Safety and Efficacy of Long-term Administration of EB-1020 Once Daily QD XR Capsules in Adults With Attention-deficit/Hyperactivity Disorder
Latest Information Update: 21 Apr 2025
At a glance
- Drugs Centanafadine (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Adverse reactions; Registrational
- Sponsors Otsuka Pharmaceutical
Most Recent Events
- 21 Apr 2025 New trial record